U.S. FDA approves first treatment option for generalized pustular psoriasis flares in adults
The U.S. Food and Drug Administration is the first regulatory authority to approve spesolimab as a treatment option for generalized pustular psoriasis (GPP) flares in adults, Boehringer Ingelheim announced today. Spesolimab, marketed in the U.S. as SPEVIGO®, is a novel, selective antibody that blocks the activation of the interleukin-36 receptor (IL-36R), a signaling pathway within the immune system shown to be involved in the pathogenesis of GPP.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220901005863/en/
“GPP flares can greatly impact a patient’s life and lead to serious, life-threatening complications,” said Mark Lebwohl, M.D., lead investigator and publication author, and Dean for Clinical Therapeutics, Icahn School of Medicine at Mount Sinai, Kimberly and Eric J. Waldman Department of Dermatology, New York. “The approval of spesolimab is a turning point for dermatologists and clinicians. We now have an FDA-approved treatment that may help make a difference for our patients who, until now, have not had any approved options to help manage GPP flares.”
“This important approval reflects our successful efforts to accelerate our research with the aim to bring innovative treatments faster to the people most in need,” said Carinne Brouillon,Member of the Board of Managing Directors, responsible for Human Pharma, Boehringer Ingelheim. “We recognize how devastating this rare skin disease can be for patients, their families and caregivers. GPP can be life-threatening and until today there have been no specific approved therapies for treating the devastating GPP flares. It makes me proud that with the approval of SPEVIGO® we can now offer the first U.S. approved treatment option for those in need.”
The FDA’s approval of spesolimab is based on results from the pivotal EFFISAYIL® 1 Phase II clinical trial.1 In the 12-week trial, patients experiencing a GPP flare were treated with spesolimab or placebo. Most patients at the outset of the trial had a high, or very high, density of pustules, and impaired quality of life. After one week, 54% of patients treated with spesolimab showed no visible pustules compared to placebo (6%).1
In addition to the U.S. approval, spesolimab is currently under review by several other regulatory authorities. To date, spesolimab has received Breakthrough Therapy Designation in the U.S., China and Taiwan, Priority Review in the U.S. and China, Orphan Drug Designation in the U.S., Korea, Switzerland and Australia, Rare Disease Designation and fast track in Taiwan, for the treatment of GPP flares. The European Medicines Agency validated the marketing authorization application for spesolimab in GPP in October 2021 and the submission is currently under evaluation.
Distinct from plaque psoriasis, GPP is a rare and potentially life-threatening neutrophilic skin disease, characterized by episodes of widespread eruptions of painful, sterile pustules. Given that it is so rare, recognizing the symptoms can be challenging and consequently lead to delays in diagnosis.
For the full press release and link tor ‘Notes to Editors’ please click here: https://www.boehringer-ingelheim.com/human-health/skin-diseases/fda-approves-first-gpp-flare-treatment
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Media + PR
Dr Petra Kienle
Phone: +49 (6132) 77-143877
Fax: +49 (6132) 77 6601
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
O-RAN ALLIANCE Announces Key Topics at the Open RAN Summit at Fyuz, Global PlugFest Fall 2022 and a New Set of O-RAN Demos26.9.2022 19:45:00 CEST | Press release
O-RAN ALLIANCE: Key topics at the Open RAN Summit @ Fyuz 2022 brought by the O-RAN ALLIANCE The Open RAN Summit @ Fyuz, powered by O-RAN ALLIANCE and Telecom Infra Project, will take place in Madrid on October 25-26, 2022. As a main partner of the event, O-RAN ALLIANCE brings key topics to the agenda and invites utmost erudite speakers. Join the event to get the latest news and views on: O-RAN ALLIANCE and TIP cooperation Established operators worldwide showcasing how they are overcoming Open RAN challenges and moving forward with deployments Open RAN cloudification options and realities Achievements and challenges on the open RAN supply side, along with insights into value chain evolution Rich variety of Open RAN deployment paths tailored to meet diverse operator’s needs How the testing and integration work is critical to making Open RAN a success What’s behind the hype of the RAN Intelligent Controllers and how an empowered ecosystem delivers customized operator value And many more i
Boomi Appoints Mark Fields to Its Board of Directors26.9.2022 18:00:00 CEST | Press release
Boomi™, the intelligent connectivity and automation leader, today announced the appointment of former CEO of Ford Motor Company Mark Fields as an independent, non-executive member of its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220919005019/en/ Boomi Appoints Mark Fields to Board of Directors (Graphic: Business Wire) “As Boomi continues its rapid growth, we’re excited to attract sought-after leaders to join our mission to make the world a better place by connecting everyone to everything, anywhere,” said David Meredith, CEO at Boomi. “Mark’s exceptional track record as a leader, advisor and visionary — coupled with our award-winning technology and innovation — helps position Boomi to deliver superior outcomes for even more customers.” Mark Fields As former CEO of Ford Motor Company, Fields brings three decades of experience driving innovation and business transformation initiatives across multi-bill
ONWARD Announces Appointment of Vivian Riefberg to Board of Directors26.9.2022 17:30:00 CEST | Press release
ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury, today announced the appointment of Vivian Riefberg as a non-executive member of its Board of Directors. Ms. Riefberg will join the Board immediately and will serve on its Compensation Committee. Her appointment to the Board will be presented for shareholder approval at the next Annual General Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220926005494/en/ Vivian Riefberg joins the ONWARD Medical Board of Directors (Photo: Business Wire) “Vivian Riefberg is a distinguished expert in health care, government, and strategy. I am excited and honored to welcome her to our Board”, said Dave Marver, Chief Executive Officer. “Vivian brings a rich understanding of the institutions with which we will collaborate to bring our novel therapies to market
ComTech Gold $CGO Becomes the First 100% Gold Backed Token to Receive Shariah Certification in the MENA Region26.9.2022 17:25:00 CEST | Press release
ComTech FZCO receives Shariah Compliance Certification for ComTech Gold Token (CGO), becoming the first in industry to be awarded a Shariah certification for Gold tokenization product in the Region. Shariah certification (Fatwa) was issued by Amanie Advisors Ltd, an entity specialising in field of Shariah-compliant investments and Islamic finance solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220926005591/en/ ComTech Gold $CGO receives Shariah Certification from Amanie Advisors (Photo: AETOSWire) ComTech FZCO, a Dubai-based company redefining tokenization infrastructure (for real-world assets), started with digitization of Gold powered by XDC Network. ComTech Gold ‘CGO’ is listed on Global Exchanges like LBank, Bitrue. Investors can buy CGO by opening an account with these exchanges. Investors can hold tokens within the exchange wallets or with any of the Internationally accepted wallets like D’cent, Guarda, or th
Actylis Debuts, Signaling the Creation of an Integrated Global Specialty Ingredients Manufacturing and Sourcing Powerhouse26.9.2022 17:00:00 CEST | Press release
Actylis, a leading global manufacturer and sourcing expert of critical raw materials and performance ingredients for the life sciences and specialty chemicals markets, made its debut today. The new company combines Aceto and 10 industry specialists into an integrated global ingredient powerhouse. Actylis (“Ac-till-iss”) is the culmination of an ambitious initiative launched several years ago to address the major unmet need for better and more dependable access to critical raw materials and performance ingredients essential for the manufacture of highly regulated products in key industries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220926005021/en/ To achieve this goal, Actylis has integrated leading specialty ingredient manufacturing and sourcing companies, including A&C, A&C Bio Buffer, Aceto, Biotron Laboratories, Cascade Chemistry, Finar, Inter-Actifs, IsleChem, Pharma Waldhof, Syntor Fine Chemicals and Talus into on
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom